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Aim: Report the outcome of 8 patients (pts) with breast cancer (BC) treated with Tamoxifen
(TAM)  that developed malignant mixed Müllerian tumor (MMMT) and rare uterine sarcoma
(RUS).
Patients and methods: Retrospective study based on data collected from the department medi-
cal records between April 1999 and September 2010 among 583 pts with endometrial cancer,
36  pts with MMMT and RUS histopathology. Among them, 8 pts underwent TAM between 4
and  10 years due to a previous diagnosis of BC; all pts were post-menopausal with regular
gynecological surveillance; 6 pts (75%) with abnormal uterine bleeding. The diagnosis of 6
pts  (MMMT) and 2 pts (RUS) occurred at median interval of 8 years (range 4–12) after ini-
tial  BC treatment. Pts underwent surgical treatment and were staged as stage I (3pts), IIIA
(3pts)  and IIIC (2 pts) (FIGO 1988); followed by whole pelvis irradiation (50 Gy) and intracav-
itary HDR brachytherapy boost (24 Gy). Two pts underwent chemotherapy (CT). Overall and
disease free survival was calculated by Kaplan Meier method.
Results: With a median follow-up of 47 months (range 17–130), 3 pts remain alive recurrence-
free  of BC and RUS. Four pts died with distant metastasis within the ﬁrst follow-up year,
without BC. One pt died from non-related cancer cause. No evidence of local recurrence was
found in the whole group of pts. At two years, DFS and OS were 40% and 80%, respectively.Conclusion: As reported in the literature, TAM administration and causal effect on MMMT
and  RUS in BC pts is still unknown. No reports about outcome from these speciﬁc pts werefound.
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1.  Background
Breast cancer is the most common cancer in women
worldwide, comprising 22% of all female cancers (WHO).1
Approximately 75% of all cases are diagnosed in post-
menopausal women. About one half of breast cancers have
favorable biological characteristics (hormone receptor positive
disease (ER)), being the rational to the use of TAM. It has been
used since the 1980s and is proven to be an effective drug in
the adjuvant and metastatic settings.2–4
Uterine MMMT  was considered as a rare uterine can-
cer (1.5%),5 and has been associated to TAM use, as have
been rare uterine sarcomas such as stromal sarcoma6,7 and
leiomyosarcomas (LMS).8–11 These uterine malignancies are
highly aggressive neoplasia with a tendency to high stage at
diagnosis and a poor prognosis. In addition, TAM increases the
incidence of endometrial carcinoma from 1 to 2 cases per 1000
women per year12–14 and of uterine sarcoma from 0.04 to 0.17
cases per 1000 women per year.15
The authors report clinical ﬁndings in eight cases of uterine
MMMT  and RUS following TAM adjuvant treatment for BC and
a review of the literature is presented.
2.  Patients  and  methods
The clinical cases which form the basis of the study were
retrieved from the archive of the Radiation Oncology Depart-
ment, at Hospital Santa Maria – CHLN. This retrospective
analysis includes 8 patients who underwent treatment for
breast and uterine cancer, the latter diagnosed between April
1999 and September 2010.
During this period, 583 pts with endometrial cancer were
referred to the Department including 36 carcinosarcomas and
uterine sarcomas, all having undergone RT adjuvant treat-
ment.
These 8 pts underwent a total abdominal hysterectomy
with bilateral oophorectomy and salpingectomy and in two
cases pelvic lymph node dissection was performed. The
uterine histopathology was classiﬁed as: malignant mixed
Müllerian tumor (5 carcinosarcomas homologous and 1 het-
erologous malignant cartilage) and high grade LMS  in 2 pts.
According to the International Federation of Gynecology and
Obstetric (FIGO 1988) classiﬁcation, the pts were staged as fol-
lows: 3 pts stage I; 3 pts stage IIIA and 2 pts stage IIIC (Table 1).
Table 1 – Patients and uterine neoplasia characteristics.
Case Age diagnosis
BC/RUR
Duration tamoxifen
therapy (years)
1 49/61 5 
2 63/70 6 
3 58/66 5 
4 75/79 10 
5 63/71 5 
6 47/51 5 
7 59/71 5 
8 70/81 6 
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Patients received adjuvant external whole pelvic radiation
therapy 3D conformal Radiation therapy (3DCRT) with doses of
50 Gy (2.0 Gy per fraction) with a pelvic TC based planning (TPS
XIO®), irradiation technique with 4 ﬁelds (box technique) with
10–15 MV photon beam energy, followed by brachytherapy
intracavitary boost with vaginal applicators with a prescript
dose of 24 Gy (6 Gy in 4 fractions/weekly), throughout Ir192 HDR
brachytherapy PLATO® orthogonal radiographs 2D planning
restraining by bladder and rectum dose (OAR) for ICRU 38 ref-
erence points. Total doses to the pelvis OAR EQD2/ 3 = 43.2 Gy
(BT HDR). Total treatment time was within 7–10 weeks.
Systemic treatment was adjuvant to surgery with 6 cycles
(every 28 days) of combination CT [Carboplatin (AUC 5–7,
intravenously (IV) D1) followed by Paclitaxel (175 mg/m2 IV
3 h D1)] in case 6. CT scheme in case 7 was gemcitabine
675 mg/m2 on D1 and D8 IV over 90 min, followed by docetaxel
75 mg/m2 on D8 IV over 1 h and subcutaneous granulocyte-
colony-stimulating factor (GCSF) – 150 m/m2 given on D9
through D15.
3.  Statistical  methods
Overall survival (OS) was deﬁned from date of uterine
MMMT/sarcoma diagnosis to date of death or last follow-up.
Disease free survival (DFS) was deﬁned from date ending uter-
ine MMMT/sarcoma treatment until LR or DM.  The Kaplan
Meier method was used to estimate survival curve distribu-
tions. Statistical analysis was performed using SPSS software
(version 15.0).
4.  Results
Patients had BC diagnosis at a median age of 61 years (range
47–74 years). All underwent radiation therapy to BC and two
pts received CMF (3 weeks – alkylator cyclophosphamide 600
(d1); 5-ﬂuorouracil 600 (d1); methotrexate 40 (d1) scheme of
chemotherapy). TAM in a dose of 20 mg/day was administered
between 4 and 10 years.
None of the pts had prior pelvic irradiation with castration
purpose.All pts had regular gynecological surveillance. Seventy ﬁve
percent of the pts had abnormal uterine bleeding and 2 pts had
endometrial polyp on routine ultrasound. Uterine malignant
mixed Müllerian tumor (MMMT) and sarcoma occurred at an
Histologies RUS FIGO staging
High grade leiomyosarcoma IB
MMMT (carcinosarcoma homologous) IIA
MMMT (carcinosarcoma) homologous IIIC
MMMT (carcinosarcoma homologous) IB
MMMT (heterologous – malignant cartilage) IA
MMMT (carcinosarcomahomologous) IIIC
High grade leiomyosarcoma IIIA
MMMT (carcinosarcoma homologous) IIIA
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Table 2 – Patients and treatment characteristics.
Case Treatment WPRT  + BT HDR CT Recurrence/months
after RT
Outcome
1 TAH/BSO 50Gy + 24Gy Lung and brain/12 Died of tumor at 25
months
2 TAH/BSO 50Gy + 24Gy Peritoneal serosa/11 Died of tumor at 33
months
3 TAH/BSO and LND 50Gy + 24Gy Peritoneal serosa/8 Died of tumor at 19
months
4 TAH/BSO 50Gy + 24Gy Lung/1 Died of tumor at 21
months
5 TAH/BSO 50Gy + 24Gy Alive at 100 months
6 TAH/BSO and LND 50Gy + 24Gy 6× [Carboplatin (AUC 5–7, IV
D1) + PTX (175 mg/m2 IV 3 h D1)]
Alive at 126 months
7 TAH/BSO 50Gy + 24Gy Gemcitabine (675 mg/m2 IV
D1 + D8-90 min) + DTX (75 mg/m2
IV D8-1 h)
PA  lymph nodes/2 Died at 25 months
non cancer-related
8 TAH/BSO 50Gy + 24Gy Alive at 17 months
TAH – total abdominal hysterectomy; BSO – bilateral oophorectomy and salpingectomy; LND – pelvic lymph node dissection; WPRT – whole
pelvic radiation therapy; BT HDR – brachytherapy high dose rate; CT – che
intravenously; D – day; PTX – paclitaxel; DTX – docetaxel.
Graph 1 – Disease-free survival (Kaplan Meier curves on thmotherapy; RT – radiation therapy; AUC – area under the curve; IV –
is group of patients with uterine sarcomas after BC).
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average of 8 years (range 4–12 years) after BC initial treatment.
At the time of uterine MMMT  and RUS diagnosis, all pts were
postmenopausal with a median age of 69 years (range 51–81
years).
With a median follow-up of 47 months (range 17–130), four
pts developed distant metastasis in the ﬁrst year of follow-up.
M1 disease was localized in the lung (1 month), another pt had
lung and rare brain metastasis (12 months) 2 pts had periton-
eal serosa metastasis (8 and 11 months) and para-aortic lymph
nodes (2 months) (Table 2).
One pt died at 25 months of follow-up from non-related
cancer cause. The median overall survival was 36 months
(95% CI 23–49) for this group of pts; 3 pts were alive, without
Graph 2 – Overall survival (Kaplan Meier curves on thisiotherapy 1 8 ( 2 0 1 3 ) 251–260
evidence of BC nor uterine disease after a median follow-up
of 81 months (range 17–126).
Two-year local control (LC), disease-free survival (DFS) and
overall survival (OS) were 100%, 40% and 80%, respectively
(Graphs 1 and 2).
5.  DiscussionBC is the most common cancer in women, usually with an
excellent prognosis. Long-term survivors are at an increased
risk of treatment related events, belonging to a special group
of pts in clinical practice.
 group of patients with uterine sarcomas after BC).
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Table 3 – Selected NSABP tamoxifen trials.
Protocol Patient population Treatment comparison No. of randomized women Median follow-up (years)
B-14 Node-negative ER-positive BC (Tx) Tamoxifen v Placebo 2892 14.9
B-21 Node-negative ≤ 1 cm BC (Tx) RT v Tamoxifen ± RT 1009 8.0
B-24 Ductal carcinoma-in situ (Tx) Tamoxifen v placebo 1804 8.1
P-1 High risk (prevention) Tamoxifen v placebo 8306a 6.9
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Estrogen exposure is an important risk factor for endome-
rial cancer.16,17 Association with lifetime exposure to
ndogenous estrogen17 and long-term unopposed estrogen
herapy is described as underlying endometrial hyperplasia
nd cancer in postmenopausal women.16
Over the past 3 decades, TAM has been widely used in the
revention18 and treatment of hormone responsive BC pts,
emonstrated in several clinical trials to be successful in either
arly and advanced BC disease.
According to literature reported by the National Surgical
djuvant Breast and Bowel Project (NSABP), TAM decreases
he incidence of ER-positive BC by 30–60% over a period of 5
nd more  years at high risk for the disease3 (Table 3). Never-
heless, an aspect in NSABP trials has been an increased risk
f developing endometrial cancer in women who underwent
AM3,13–16,19 (Table 3). In a more  recent update of all BC NSABP
rials, the rate of endometrial cancer was 1.26 per 1000 patient
ears in women treated with TAM versus 0.58 per 1000 patient
ears in the placebo group.20
The following tables illustrate the NSABP studies (exclud-
ng pts with CT treatment) with TAM in treatment and
revention (NSABP – 14; 21; 24) of BC and the incidence of
arcoma in (NSABP P-1) (Table 4).
Selective estrogen receptor modulators (SERM), such as
rst-generation TAM, a nonestroidal triphenylethyl com-
ound, produce antagonist effect in breast tumor cells with
strogen receptors (ER). The process is the competitive binding
f TAM metabolites to ER and inhibition of the growth-
romoting activity of endogenous estrogens in breast,21 yet
ith agonist tissue-speciﬁc effects in bone, cardiovascular
Table 4 – Incidence of uterine sarcoma in NSABP
treatment trials and BC prevention trial P-1.
Protocol Sarcoma
Tamoxifen No tamoxifen
No. Ratea No. Rate
B-14 4 0.10 0 0
B-21 0 0 0 0
B-24 1 0.14 0 0
P-1 4 0.17b 0 0b
Reference:  D. Lawrence Wickerham, Bernard Fisher, Norman Wol-
mark, John Bryant, Joseph Constantino, Leslie Bernstein, Carolyn D.
Runowicz, Association of Tamoxifen and uterine sarcoma, JCO 20
(June (11)) (2002) 2758–2760.
a Rate per 1000 women-years.
b Rate per 1000 women-years, Pts with intact uterus at
randomization.system22 and endometrium including thickness, stromal
ﬁbrosis, cystic changes and polypoid formation have been
described in pts that underwent TAM.23,24
Follow-up of pts in TAM treatment, include an annually
disease-speciﬁc history, a gynecological evaluation with a
Papanicolaou smear and pelvic examinations with endome-
trial ultrasound assessment. Transvaginal ultrasonography is
not recommended for routine screening. Even though, in these
high risk pts an endometrial measurement on ultrasonogra-
phy of more  than 8 mm or abnormal bleeding, discharge,
abnormal glandular cells on Papanicolaou smear an inva-
sive procedure should be done to evaluate endometrium.25,26
Abnormal vaginal bleeding is the most common presenting
symptom in all types of uterine neoplasia, occurring between
75 and 95% of the pts. In the current series of pts, this symptom
occurred in 75%.
In endometrial tissue, TAM has estrogenic effect not
only in epithelial proliferation but also in the mesenquimal
component. Decensi et al.27 compared the endometrium of
TAM-treated BC pts and controls and observed an antiprolifer-
ative effect of TAM on the epithelium and a growth-promoting
effect on the stroma, suggesting that the endometrial pro-
liferation is mediated by the stromal component. TAM dose,
duration and association with other known risk factors (obe-
sity, arterial hypertension, diabetes mellitus, nulliparous or
previous use of hormonal replacement therapy) may increase
the risk of uterine malignancies.
The ﬁrst evidence of the carcinogenicity of TAM was
described in the Stockholm trial with doses of 40 mg  during
2–5 years, increasing the risk of endometrial cancer RR 6, 4.28
All pts in this current series received 20 mg  of TAM between 4
and 10 years. None of the pts had prior pelvic irradiation with
castration purpose since pelvic irradiation has been thought to
be a risk factor to uterine sarcomas. Schaepman-Van Geuns12
reported that previous irradiation was not a determinant eti-
ologic factor in these tumors.
The ﬁrst available report of Tamoxifen-related MMMT was
described by Hardell29 in 1988, then there were occasional
reports in the mid  1980s and 1990s of uterine MMMT  and
sarcoma occurring in pts treated with TAM. Pharmaceutical
database worldwide contains 140 uterine sarcomas and in the
NSABP data, 9 of the 12 sarcomas were MMMT  histopathology.
Studies from 2004 indicated that the tamoxifen-related risk of
uterine corpus cancer may be especially high for some uncom-
mon  cell types, although the magnitude of risk has not been
quantiﬁed.30According to NCBI online research, until 2006, approxi-
mately 65 cases of non-epithelial neoplasia had been reported,
including MMMT (carcinosarcoma homologous and heterolo-
gous components) and RUS (LMS, stromal sarcomas).31 Few
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Table 5 – Patients characteristics in the literature.
Reference No. Age (range
years)
Dur. TAM
(range months)
Latency (range
months)
Stage Histological
type
Hardell29 1 55 72 ? ? Carcinosarcoma
Bocklage et al.77 1 54 13 ? ? Adenosarcoma
Cutili et al.78 1 44 96 ? ? MMMT
Beer et al.6 1 61 60 ? ? Stromal sarcoma
Barakat et al.79 5 66 (mean) 54 (mean) ? ? MMMT
Clement et al.80 6 59 (mean) 6–48 ? ? Adenosarcoma
Silva et al.10 1 ? ? ? ? MMMT
Clarke81 1 83 108 108 I MMMT
Altaras et al.82 1 82 108 108 ? MMMT heterologous
Magriples et al.83 2 70–71 12 12 IVB MMMT
Seoud et al.84 1 86 24 ? IIA Carcinosarcoma
Fisher et al.13 1 54–62 42–66 65 IIB Carcinosarcoma
Evans et al.85 6 43–83 36–144 ? ? MMMT
Ariad et al.86 1 65 37 37 ? ?
Fornander et al.87 1 67 24 42 I ?
Sasco et al.88 1 80 72 121 ? Carcinosarcoma
Sasco et al.89 1 4 61–76 90–156 ? ?
Mccluggage et al.90 19 47–91 1–15 ? IA–IVA MMMT
Treilleux et al.91 6 44–77 30–120 ? ? Carcinosarcoma,
adenosarcoma, MMMT
Dumortier et al.92 1 64 60 120 IB MMMT
Fotiou et al.93 2 67–72 72–84 72–84 III Carcinosarcoma
Kloos et al.94 5 50–84 60–240 84–240 IIA–IVA Carcinosarcoma
Hubalek et al.95 1 40 24 24 ? MMMT
Yildirim et al.96 4 61–73 36–132 ? ? MMMT, leiomyosarcoma
Arenas et al.31 3 ? 36–84 60–84 I Carcinosarcoma,
adenosarcoma
Magnani et al.97 1 54 60 ? ? MMMT
Lavie et al.98 4 ? 24 to >48 ? ? Carcinosarcoma,
rabdomyosarcoma, mixed
mesodermal tumor
Leung et al.99 2 ? ? ? ? Carcinosarcoma
This series 8 51–81 60–120 
Total 88 40–90 6–240 
cases have been published; Table 5 summarizes, by author,
the characteristics of the pts which have been found in the
literature.
The rarity of uterine sarcoma powerless the causal effect
among TAM use and the incidence of the disease. In NSABP
data, Bergman et al. and Zelmanowicz et al.32,33 showed an
increased rate of endometrial adenocarcinomas and MMMTs,
as did some retrospective studies9,10 considering dose and
TAM duration.
In the past, there has been no standardized nomenclature.
Potential pitfall in diagnosing sarcomas is the variability of the
threshold for distinction between atypical benign tissues and
clearly malignant tissues. A histopathology review was done
to resolve the doubt.
The new WHO  and FIGO classiﬁcation for uterine sarcomas
since 2009 include:
(1) Leiomyosarcoma; endometrial stromal sarcomas and
undifferentiated or pure heterologous;
(2) Adenosarcomas;
(3) Carcinosarcoma (malignant mixed Müllerian tumor ormalignant mixed mesenquimal tumor – MMMT), the
latter staged and treated as endometrial carcinomas.34
Although according to this new classiﬁcation, carcinosar-
comas of the uterus should no longer be identiﬁed as uterine48–144 IA–IIIC MMMT, leiomysarcoma
12–240
sarcomas,35 we joined in our series 6 pts with MMMT  and
2 with LMS, all high risk uterine histopathologies in TAM
administration.
Uterine sarcoma is a rare tumor and represents 1% of all
gynaecologic malignancies and 4–9% of all malignant uter-
ine neoplasms.36,37 The majority of pts are post-menopausal
with a poor prognosis (5 years survival of 50%), diagnosed in
advanced stages.
In a large French case–control study, BC pts who  developed
endometrial cancer and TAM treatment had a more  advanced
disease and a poorer prognosis than those with endometrial
cancer without prior TAM.38
Danish BC Cooperative Group (DBCG) during 1977–2001,
analyzed BC survivors and reported a group of pts that devel-
oped second primary cancers. Cancer incidence rates of the
Danish population were used for calculation of standardized
incidence ratios (SIRs). The authors concluded that there was
an increased risk of cancer of corpus uteri (SIR = 1.83 vs 1.04)39
for TAM treated pts, compared to non-TAM treated pts.
Uterine sarcomas spread by lymphatic and hematogenouspaths40–44 as well as by local extension and peritoneal spread.
Several studies have addressed the metastatic pattern of uter-
ine sarcomas. Chen42 revised nodal metastases in 20 pts with
clinical stage I uterine sarcomas: fourteen pts with MMMT,  4
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ith LMS,  and 2 with endometrial stromal sarcoma (ESS). He
ound nine pts (45%) with lymph node metastases (6 with para-
ortic and pelvic node involvement and 3 with pelvic node
nvolvement). Rose et al.40 reviewed the autopsy ﬁndings of
3 pts with uterine sarcoma, including 43 pts with MMMT,
9 with LMS,  9 with ESS and 2 with endolymphatic stromal
yosis. The peritoneal cavity and omentum were the most
requently involved sites (59%), followed by the lung (52%),
elvic (41%) and para-aortic (38%) lymph nodes, and liver
arenchyma (34%). Of note, the presence of lung metastasis
as not associated with pelvic or para-aortic nodal metastasis
r intraperitoneal disease.
A non-uniform surgical management in MMMT has been
eviewed by Vorgias et al.44 who described the rationale for
ymphadenectomy, which, beyond staging information, offers
 measurable survival beneﬁt. However, pelvic lymphadenec-
omy the histopathology non-MMMT  has still no agreement
or the majority of the authors.45
As adjuvant treatment, all pts in the current series received
xternal whole pelvic 3DRT in conventional fractionation fol-
owed by a HDR brachytherapy intracavitary boost. BT dose
nd technique can also be optimized in these particular cases
mproving results.46–48
Adjuvant radiotherapy in RUS non-metastatic pts is
onﬂict-ridden, as nowadays carcinosarcomas were excluded.
 number of reports have documented the pattern of recurr-
nces in pts with stage I or II sarcomas, and showed in those
ho  received radiation therapy to the pelvis a statistically signif-
cant reduction of recurrences within the radiation treatment
eld.49 A recent phase III randomized trial in stage I and II uter-
ne sarcomas reported that post-operative pelvic radiotherapy
id not improve survival for LMS  when compared with obser-
ation, but in a 20-year center analysis study published in the
iterature the authors observed a decreased pelvic failure.50–54
Adverse prognostic factors for MMMT  were recognized,55–58
elvic recurrence rate was 56%, whereas the distant metas-
asis rate was 45%,59 demonstrating a meaningfully higher
elative risk for pelvic recurrence than that seen in pts with
MS.57,60–62 Pelvic recurrence rate in MMMT  corroborates the
se of adjuvant therapy for loco-regional control and also
sserts that surgery alone, for disease apparently limited to
he uterus, is not enough to achieve a pelvic control of the
isease. Studies showed a 53% reduction in the risk of LRF at
 years,63 even though survival beneﬁt has not been demon-
trated in randomized trials.34,61,64–70
Few reports address the second neoplasia treatment out-
ome in these speciﬁc cases.71
The published GOG 150, a phase III study of the whole
bdominal radiotherapy versus ifosfamide/mesna with cis-
latin in pts with optimally debulked stage I–IV MMMT, did
ot ﬁnd a statistically signiﬁcant advantage in the recurrence
ate or survival for adjuvant CT over RT in pts with uterine
arcinosarcoma.72
.  Conclusionor most women, the beneﬁts of TAM in preventing a recur-
ence of BC outweigh by far the potential risk of uterine cancer.
urthermore, beneﬁt from the TAM has evident survival. In
1therapy 1 8 ( 2 0 1 3 ) 251–260 257
the adjuvant setting, TAM is recommended for a maximum
of 5 years.73 Nowadays, other inhibitors are used in clinical
practice, well-tolerated adjuvant therapy for postmenopausal
women with predictable and apparently more  preventable and
manageable adverse effects than those associated with TAM,
yet needing a longer follow-up.74–76 Gynecological surveil-
lance and long time follow-up is the main key.
This case report as well as other from the literature,15,76
may empower the relation between TAM treatment and causal
effect in uterine MMMT and sarcomas. Reports of second
tumors, therapeutic management and outcomes, although
the known dismal prognosis show acceptable outcomes in
some pts. This ought to prospect future research in areas
including surgery, RT, and CT, to increase the probability of
disease control.
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